Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Paradigm Therapeutics

HQ: Mt. Pleasant, SC source · paradigmtherapeutics.com ↗ · Southeast

Clinical Phase 3

Keywords: epidermolysis bullosa

Location: Mt. Pleasant, SC · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Nov 15, 2026 Trial start Phase 3: An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa source ↗
Jul 21, 2026 Trial start Phase 3: Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa source ↗

Upcoming milestones

May 17, 2027 (ESTIMATED) · Phase 3 · Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa · NCT07482787
Sep 19, 2027 (ESTIMATED) · Phase 3 · An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa · NCT07482813

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07482813	An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa	Phase 3	Not yet recruiting	Nov 15, 2026	Sep 19, 2027 (estimated)
NCT07482787	Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa	Phase 3	Recruiting	Jul 21, 2026	May 17, 2027 (estimated)